Investing in stocks that aren't performing well can be a good move, but only if there are good reasons to think they will recover. That isn't the case for many companies that have lagged broader equities....
Earnings To Watch: Incyte (INCY) Reports Q4 Results Tomorrow
The analyst sees 2025 as a challenging year due to Eylea headwinds but expects growth to accelerate in 2026, driven by strong eczema treatment sales from the company’s Dupixent drug.
These stocks are looking to return varying amounts of capital to shareholders using buybacks. One fintech's buyback capacity is equal to 25% of its market cap.
Ferrari N.V.’s (RACE) shares jumped 7.1% after the company reported fourth-quarter 2024 adjusted earnings per share of $2.28, surpassing the Zacks Consensus Estimate of $1.89.Shares of Regeneron Pharmaceuticals...
News of a significant earnings beat propelled Regeneron Pharmaceuticals (NASDAQ: REGN) to a nearly 5% share price gain on the second trading day of the week. The company posted its fourth-quarter and full-year...